

# Protein profiling and functional analysis of liver mitochondria from rats with nonalcoholic steatohepatitis

YANTING YOU<sup>1,2\*</sup>, YUXING ZHANG<sup>1,2\*</sup>, YUANYUAN LU<sup>1,2</sup>, KEKE HU<sup>1,2</sup>,  
XIAOHU QU<sup>1,2</sup>, YONGZHAG LIU<sup>1,2</sup>, BIN LU<sup>1,2</sup> and LIQIN JIN<sup>1-3</sup>

<sup>1</sup>Key Laboratory of Laboratory Medicine, Ministry of Education, and Zhejiang Provincial Key Laboratory of Medical Genetics; <sup>2</sup>School of Laboratory Medicine and Life Science; <sup>3</sup>School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, P.R. China

Received April 7, 2016; Accepted March 6, 2017

DOI: 10.3892/mmr.2017.6893

**Abstract.** Mitochondrial dysfunction is closely associated with the pathogenesis of nonalcoholic steatohepatitis (NASH). The aim of the present study was to comprehensively determine mitochondrial abnormalities in NASH by detecting the proteomics in liver mitochondria in a NASH rat model, which was induced for 16 weeks by the provision of a high fat and high cholesterol diet (HFD). Serum parameters, including triglycerides, total cholesterol, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol were determined, and hematoxylin and eosin staining of liver tissues was examined

to evaluate the NASH rat model. Various parameters associated with mitochondrial function were examined, including mitochondrial DNA (mtDNA) copy number, mitochondrial membrane potential (MMP) and mitochondrial respiratory chain complex (MRC) activity. The mitochondrial proteomics were analyzed and identified using isobaric tags for relative and absolute quantitation labeling coupled with two-dimensional liquid chromatography-tandem mass spectrometry. The identified proteins were classified and grouped using the Blast2GO program against the non-redundant protein database, the Kyoto Encyclopedia of Genes and Genomes database and the Cluster of Orthologous Groups of proteins database. Compared with the control, mtDNA copy number, MMP, and activities of MRC I and III were decreased markedly in the HFD group. A total of 18 upregulated and 13 downregulated proteins were identified, with a significant 1.2-fold difference between the control and NASH groups. The dysregulated proteins were closely involved in mitochondrial oxidative phosphorylation, the lipid metabolic process and fatty acid  $\beta$ -oxidation. The results of the present study provide important proteomic information regarding liver mitochondria in NASH and serve as a basis for further detailed investigations of the pathogenesis of NASH.

*Correspondence to:* Professor Liqin Jin, School of Basic Medical Sciences, Wenzhou Medical University, 7 a209 Chashan Campus, Chashan University Town, Wenzhou, Zhejiang 325035, P.R. China  
E-mail: liqinjinwmu@139.com

Professor Bin Lu, School of Laboratory Medicine and Life Science, Wenzhou Medical University, 4b 521 Chashan Campus, Chashan University Town, Wenzhou, Zhejiang 325035, P.R. China  
E-mail: lubmito@wmu.edu.cn

\*Contributed equally

**Abbreviations:** NASH, nonalcoholic steatohepatitis; HFD, high fat and high cholesterol diet; iTRAQ, isobaric tags for relative and absolute quantitation; 2D LC-MS/MS, two-dimensional liquid chromatography-tandem mass spectrometry; KEGG, Kyoto Encyclopedia of Genes and Genomes; NAFLD, nonalcoholic fatty liver disease; HCC, hepatocellular carcinoma; ROS, reactive oxygen species; ATP, adenosine triphosphate; SCD, standard chow diet; TC, total cholesterol; TG, triglyceride; LDL-C, low-density lipoprotein; HDL-C, high-density lipoprotein; H&E, hematoxylin and eosin; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; NADH, ubiquinone oxidoreductase; CS, citrate synthase; MMP, mitochondrial membrane potential; mtDNA, mitochondrial DNA; MRC, mitochondrial respiratory complex; ACSM2, acyl CoA synthetase; FPP, farnesyl pyrophosphate

**Key words:** mitochondrial function, nonalcoholic steatohepatitis, isobaric tags for relative and absolute quantitation, rat model

## Introduction

Nonalcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disease, and comprises a wide range of pathological changes in the liver, from non-progressive steatosis to nonalcoholic steatohepatitis (NASH), advanced fibrosis and cirrhosis, ultimately leading to hepatocellular carcinoma (HCC) (1). NASH is characterized by lobular inflammation, hepatocellular ballooning and fibrosis, and is key in the progression to cirrhosis and HCC (2). Day and James described a two-hit theory (3), regarding the hepatic triglyceride accumulation as the first hit and mitochondrial dysfunction, oxidative stress and inflammatory factors as the second hit (4). Substantial evidence has indicated that mitochondrial dysfunction is directly associated with the pathogenesis of NASH and has suggested that NASH is a mitochondrial disease (5,6). Mitochondrial dysfunction impairs lipid metabolism and induces the overproduction of reactive oxygen species (ROS),

which triggers the peroxidation of lipids and apoptosis of hepatocytes (7). In addition, this can decrease the activity of the mitochondrial respiratory chain (MRC), which further impairs adenosine triphosphate (ATP) synthesis and enhances oxidative stress (7). However, the alterations in mitochondrial proteomics in response to NASH remain to be fully elucidated.

In our previous study, a high fat and high cholesterol diet (HFD) was used to establish a NASH rat model, which is more similar to dietary conditions, compared with the methionine-choline-deficient diet in humans (8). To date, using the NASH rat model, there has been no attempt to establish a comparative proteome profile of liver mitochondria using isobaric tags for relative and absolute quantitation (iTRAQ) technology coupled with two-dimensional liquid chromatography-tandem mass spectrometry (2-D LC-MS/MS) analysis.

Compared with traditional 2-D gel electrophoresis, it is easier to analyze eight samples simultaneously using iTRAQ technology, thus enhancing throughput, and increasing sensibility and accuracy (9). To the best of our knowledge, the present study using the NASH rat model is the first to perform proteomic analysis of liver mitochondria using iTRAQ technology, to provide novel insights into the pathogenesis and progression of NASH via mitochondrial protein profiling.

## Materials and methods

**Animal models of NASH.** Eight-week-old male Sprague-Dawley rats weighing ~320 g were purchased from the Laboratory Animal Centre of Wenzhou Medical University (Wenzhou, China). Under a 12-h light-dark cycle and controlled temperature ( $23\pm 2^\circ\text{C}$ ), all rats were raised under specific pathogen-free conditions with free access to water and food. The animals were acclimatized to the laboratory conditions for 1 week prior to the experiments and were randomly divided into two groups: Control group ( $n=6$ ) and HFD group ( $n=10$ ). The rats in the control group and the HFD group were respectively fed with a standard chow diet (SCD) and a high fat diet (1% cholesterol, 19% lard and 80% SCD) for 16 weeks. The body weights of the rats were measured weekly. The rats were sacrificed following overnight fasting. All protocols and procedures conformed to the guidelines of the Laboratory Animal Ethics Committee of Wenzhou Medical University, and all efforts were made in order to minimize the suffering and the number of animals used.

**Blood and liver sample preparation.** Following sacrifice, blood samples from the abdominal vein of the rats were collected in coagulation-promoting tubes and centrifuged at 1,500 g for 15 min at  $4^\circ\text{C}$  (Eppendorf 5810R; Eppendorf, Hamburg, Germany) to obtain the serum for biochemical analysis, which was stored at  $-80^\circ\text{C}$  prior to analysis. The levels of glucose, total cholesterol (TC), triglyceride (TG), low-density lipoprotein (LDL-C) and high-density lipoprotein (HDL-C) were measured using an automated biochemistry analyzer (Hitachi, Tokyo, Japan). The livers were excised, cleaned with ice-cold phosphate-buffered saline and weighed immediately. The left lobes of each liver were then fixed in 4% paraformaldehyde solution for further morphological analysis using hematoxylin and eosin (H&E) staining, with images captured using a Nikon microscope (Nikon E-100 A12.0705; Nikon

Corporation, Tokyo, Japan). Additionally, sections of the liver tissue were added to a volume of storage medium containing 20% dimethyl sulfoxide, 0.21 M mannitol and 0.07 M sucrose (pH 7.5) for mitochondrial separation, and other sections were directly snap frozen in liquid nitrogen and then preserved at  $-80^\circ\text{C}$  until use (10).

**Determination of relative mtDNA copy number.** Total DNA from the liver tissues was extracted using a Blood and Cell Culture DNA Mini kit (Qiagen GmbH, Hilden, Germany). Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis was used to determine the relative mtDNA copy number. The RT-qPCR amplification reaction was performed via SYBR-Green chemistry using Bio-Rad CFX Manage 2.1 (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The mtDNA was synthesized and amplified using the following primers: ND<sub>1</sub> forward, 5'-ATTCTAGCCACATCAAGTCTTT-3' and reverse, 5'-GGAGGACGGATAAGAGGATAAT-3';  $\beta$ -actin forward, 5'-GAAATCGTGCGTGACATTAAAG-3' and reverse, 5'-ATCGGAACCGCTCATTG-3'. Each sample was analyzed in triplicate with a 20  $\mu\text{l}$  final volume containing SYBR-Green Supermix PCR 1X Master mix (Bio-Rad Laboratories, Inc.), 0.5  $\mu\text{M}$  forward and reverse primers and 100 ng DNA template. Following 3 min denaturation at  $95^\circ\text{C}$ , amplification was performed for 39 cycles, including  $95^\circ\text{C}$  for 10 sec for denaturation, and  $55^\circ\text{C}$  for 30 sec for annealing and extension. Melting curve analysis was performed at the end of each run to validate the specificity of the PCR products. The quantification of the relative mtDNA copy number was performed using the  $2^{-\Delta\Delta\text{C}_q}$  method (11), normalized to  $\beta$ -actin.

**Isolation of liver mitochondria.** The frozen liver tissues of the rats were rapidly thawed using a preheated medium of 0.4% BSA (Beyotime Institute of Biotechnology, Haimen, China), 0.25 M sucrose and 0.01 M Tris-HCl (pH 7.5) at  $45^\circ\text{C}$  in a 4:1 ratio of medium to tissue. The mitochondria were isolated as described previously (12). In brief, the liver tissues were weighed, washed and homogenized at  $4^\circ\text{C}$  in isolation buffer containing 0.5% BSA, 225 mM mannitol, 75 mM sucrose, 30 mM Tris/HCl and 0.5 mM EGTA (pH 7.4). The homogenate was centrifuged twice at  $4^\circ\text{C}$  and 740 g for 10 min to remove unbroken cells and nuclei, and at  $4^\circ\text{C}$  and 9,000 g for 10 min three times to precipitate the mitochondrial pellet and obtain the crude mitochondria. The pellet was resuspended in MRB buffer containing 250 mM mannitol, 5 mM HEPES and 0.5 mM EGTA (pH 7.4), and gently layered on top of 30% (v/v) percoll. Following 50 min of centrifugation at  $4^\circ\text{C}$  and 95,000  $\times$  g, collection and washing of the mitochondrial fraction twice, centrifugation was performed at  $4^\circ\text{C}$  and 6,300  $\times$  g for 10 min with MRB to remove the residual percoll. Using the BCA protein assay kit (Thermo; Fisher Scientific, Inc., Waltham, MA, USA) the concentration of mitochondrial protein was measured. Mitochondria were stored in  $-80^\circ\text{C}$  for proteomic analysis.

**MRC enzymatic assays.** As described above, the pellet (crude mitochondria) was resuspended in MRB and freeze-thawed three times using liquid nitrogen. All samples were measured in triplicate using a Varioskan Flash reader (Thermo Fisher Scientific, Inc.).

The specific activity of complex I, ubiquinone oxidoreductase (NADH) was analyzed according to the decrease in absorbance at 340 nm due to the oxidation of NADH. The isolated mitochondria (25  $\mu\text{g}$ ) were added into 200  $\mu\text{l}$  of the reaction buffer (195  $\mu\text{M}$  NADH, 50 mM potassium phosphate buffer, 10  $\mu\text{g}/\text{ml}$  antimycin, 10  $\mu\text{M}$  decylubiquinone and 5 mM  $\text{NaN}_3$ ) in a 96-well plate. Under the conditions of 340 nm and 30°C, the rate of oxidation of NADH was measured for 90 sec.

The specific activity of complex II (succinate dehydrogenase) was assessed by the decrease of absorbance at 600 nm due to reduction of dichlorophenol indophenols. The 200  $\mu\text{l}$  reaction buffer (270 mM potassium phosphate buffer, 200 mM succinate, 12  $\mu\text{M}$  rotenone, 7.5  $\mu\text{M}$   $\text{NaN}_3$ , 5  $\mu\text{g}/\text{ml}$  antimycin, 100 mM 2,6-dichlorophenolindophenolsodium salt and 20  $\mu\text{g}$  mitochondria protein) was equilibrated for 10 min at 30°C. Following the addition of 4  $\mu\text{l}$  of 1 mM decylubiquinone, the reaction was initiated and absorbance was measured at 600 nm for 90 sec at 30°C.

Complex III (decylubiquinol cytochrome oxidoreductase) was measured by the increase of absorbance at 550 nm due to the reduction of cytochrome *c*. The 200  $\mu\text{l}$  reaction buffer (250 mM sucrose, 100 mM Tris/HCl, 1 mM EDTA, 50  $\mu\text{M}$  cytochrome *c*, 50  $\mu\text{M}$  decylubiquinol, 45  $\mu\text{M}$  n-dodecyl- $\beta$ -d-maltoside and 7.5  $\mu\text{M}$   $\text{NaN}_3$ ) was incubated for 60 sec and the reaction was induced by adding 20  $\mu\text{g}$  of mitochondrial protein. The absorbance was measured at 550 nm for 90 sec at 30°C.

Complex IV (cytochrome *c* oxidase) was measured by the decrease of absorbance at 550 nm due to oxidization of the reduced cytochrome *c*. The mitochondria (20  $\mu\text{g}$ ) were added into 200  $\mu\text{l}$  reaction buffer, containing 9.4 mM potassium phosphate buffer, 50  $\mu\text{M}$  reduced cytochrome *c* and 450  $\mu\text{M}$  n-dodecyl- $\beta$ -d-maltoside. The reaction was detected at 550 nm for 135 sec at 30°C.

The activity of citrate synthase was assessed by alterations of thionitrobenzoate anion formation. The mitochondrial protein (20  $\mu\text{g}$ ) was added to 200  $\mu\text{l}$  reaction buffer (0.1 M Tris/HCl, 0.1 M 5,5'-dithiobis-2-nitrobenzoate, 0.3 mM acetyl-CoA, 450  $\mu\text{M}$  n-dodecyl- $\beta$ -d-maltoside and 500  $\mu\text{M}$  oxaloacetate). The absorbance was then measured at 412 nm for 270 sec. The activity of CS was expressed in nmol/min/mg, and normalized to total tissue protein content.

**ATP synthase activity.** According to the manufacturer's protocol of the ATP Synthase Enzyme Activity Microplate Assay kit (Abcam, Cambridge, UK), ADP and phosphate are produced by ATP synthase hydrolyzing ATP. The oxidation of NADH is coupled with the production of ADP and ultimately becomes  $\text{NAD}^+$ . The reaction was detected at 340 nm for 90 sec at 30°C.

**Mitochondrial membrane potential (MMP) analysis using JC-1.** MMP was determined in the crude mitochondria freshly isolated from liver tissues using a JC-1 Mitochondrial Membrane Potential Detection kit (Beyotime Institute of Biotechnology). According to the manufacturer's protocol, 50  $\mu\text{g}$  of mitochondria were stained by JC-1 and scanned at 490 nm excitation/530 nm emission and at 525 nm excitation/590 nm emission to detect green and red JC-1 fluorescence, respectively, using the Varioskan Flash reader.

**Quantitative proteomics using the iTRAQ technique.** Mitochondria were solubilized in lysis buffer (7 M urea, 2 M thiourea, 40 mM Tris, 2 mM EDTA, 1 mM PMSF, 0.2% SDS and 4% CHAPS), and sonicated at 200 W for 15 min on ice, followed by centrifugation at 4°C and 25,000 g for 20 min. The supernatant was added to 10 mM DTT (final concentration) and maintained at 56°C for 1 h, this step was for reducing the disulfide bonds in the proteins. The mixture was kept in the dark, and 55 mM IAM (final concentration) was added and incubated for 1 h in order to block the cysteines. To remove detergents, which may interfere with iTRAQ™ labeling, the protein was precipitated by the addition of five volumes of chilled acetone for 2 h at -20°C. Following centrifugation at 4°C at 25,000 g for 20 min, the pellet was dissolved in 500  $\mu\text{l}$  of 0.5 M triethylammonium bicarbonate (Applied Biosystems; Thermo Fisher Scientific, Inc.) and sonicated again. The samples were then centrifuged at 25,000 g for 20 min at 4°C. The Bradford method (Thermo Fisher Scientific, Inc.) was used to quantify the supernatant. Protein of each sample (100  $\mu\text{g}$ ) was digested with trypsin (Promega Corporation, Madison, WI, USA), at 20:1 protein to trypsin ratio, overnight at 37°C. Vacuum centrifugation was performed to dry the peptides following the digestion with trypsin. According to the iTRAQ™ reagents protocol, using 8-plex iTRAQ reagent (Applied Biosystems; Thermo Fisher Scientific, Inc.), the peptides were dissolved and samples labeled as follows: Control (CON)-2 (117 tag), CON-4 (114 tag), CON-5 (119 tag), CON-8 (116 tag), HFD-1 (113 tag), HFD-2 (118 tag), HFD-4 (115 tag) and HFD-8 (121 tag) randomly selected from the control group and HF group, respectively. Vacuum centrifugation at 4°C and 12,000 g for 10 min was performed to pool and dry the labeled peptide mixtures.

The peptide mixtures were added to 4 ml solvent A, which contained 25 mM  $\text{NaH}_2\text{PO}_4$  dissolved in 25% can (pH 2.7) and then injected into a 4.6x250 mm Ultremex SCX column, which worked with the LC-20AB HPLC Pump system (Shimadzu Corporation, Kyoto, Japan) and contained 5  $\mu\text{m}$  particles (Phenomenex, Inc., Torrance, CA, USA). A gradient of solvents was used to elute the peptides at a 1 ml/min flow rate: 10 min of 100% solvent A, 7 min of 5% solvent B, which contained 1 M KCl and 25 mM  $\text{NaH}_2\text{PO}_4$  dissolved in 25% ACN (pH 2.7), 20 min of 5-60% solvent B and 1 min of 60-100% buffer B. Finally, washing was performed for 1 min of 100% buffer B and equilibrated for 10 min in buffer A prior to the next loading. The absorbance of elution was monitored at 214 nm and the fractions were collected every 1 min. In total, 20 fractions were collected, which were desalted in a Strata X  $\text{C}_{18}$  column (Phenomenex, Inc.) and then dried them completely in a vacuum centrifuge.

Fractions were reconstituted with solvent A (2% CAN, 0.1% FA) and centrifuged for 10 min at 4°C and 20,000 g to remove the insoluble substance, and the final concentration of peptide was adjusted to 0.5  $\mu\text{g}/\mu\text{l}$ . In each fraction, using the autosampler, 5  $\mu\text{g}$  of peptide mixture was injected into a Shimadzu LC-20AD nano HPLC (Shimadzu Corporation), which had a 2 cm  $\text{C}_{18}$  trap column. Subsequently, an in-house packed analytical column (75  $\mu\text{m}$  x 10 cm,  $\text{C}_{18}$ ) was used to elute the peptides. The peptides were loaded at 8  $\mu\text{l}/\text{min}$  for 4 min and separated at a flow of 300 nl/min over 44 min with a gradient of solvent B (98% ACN and 0.1 FA). Subsequently,

the linear gradient was increased to 80% within 2 min and maintained at 80% for 4 min, followed by a return to 5% for 1 min. The effluent was analyzed using a Q-Exactive mass spectrometer (Thermo Fisher Scientific, Inc.) with nanoelectrospray and voltage set at 1.6 KV. At a resolution of 7,000 in an Orbitrap mass analyzer, full MS scans were acquired from 350-2,000 *m/z* for the detection. A fragment ion spectrum was produced via high-energy collision dissociation and the mass range of 100-1,800 *m/z* was detected in by Orbitrap mass analyzer at a resolution of 17,500. In the MS survey scan, following a dynamic exclusion duration of 15 sec, MS/MS data were obtained through data-dependent acquisition, which used the 15 most abundant precursor ions above the threshold ion count of 20,000. The automatic gain control target for full MS was  $3e^6$  and for MS/MS was  $1e^5$ , and were used to optimize the spectra generated by the Orbitrap analyzer.

Protein identifications were performed using Discoverer 1.2 (Thermo Electron, San Jose, CA, USA), compared with a database containing the UniprotRat sequences, using the Mascot search engine (version 2.3.02; Matrix Science, London, UK). In the identification of proteins, which allowed for one missed cleavage in the trypsin digestion, the tolerance of the peptide mass in MS was 20 ppm and for fragmented ions was 0.05 Da. The conversion of N-terminal glutamine to pyroglutamic acid, oxidation of methionine and tyrosine labeled by iTRAQ-8-plex were set as the potential variable modifications. The carbamidomethylation of cysteine at the N-terminal of peptides and lysine labeled by iTRAQ-8-plex were considered to fix these modifications. Peptides with significance scores ( $\geq 20$ ;  $P < 0.01$ ) were counted as identified in order to reduce false peptide identification. At least one unique peptide was involved in the identification of each confident protein and at least two unique peptides were required to quantify protein. Significant changes in the quantitative protein ratios were identified by setting cut off values of a fold change  $> 1.2$  and  $P < 0.05$ . Using the Blast2GO program ([www.blast2go.com](http://www.blast2go.com)), compared with the non-redundant protein database (NR; NCBI), functional annotations, which had differential proteins, were performed. The Kyoto Encyclopedia of Genes and Genomes (KEGG; <http://www.genome.jp/kegg/>) and Cluster of Orthologous groups (<http://www.ncbi.nlm.nih.gov/COG/>) databases were used to classify and group these identified proteins.

**Western blot analysis.** The proteins levels of NADH dehydrogenase 1 $\alpha$  subcomplex subunit 5 (Ndufa5), NADH dehydrogenase iron-sulfur protein 6 (Ndufs6), ATP synthase  $\alpha$  subunit (ATP5A), transcription factor A, mitochondrial (TFAM) and cytochrome b (CytB) from the liver mitochondria of the control and HFD groups were measured using western blot analysis. The proteins were extracted as described above in the 'Isolation of liver mitochondria' section and quantified by BCA Protein assay kit (Thermo Fisher Scientific, Inc.). The proteins (20  $\mu$ g) were separated on an SDS-PAGE gel and transferred onto nitrocellulose membranes (Bio-Rad Laboratories, Inc.), and then blocked with 5% nonfat milk buffer for 1.5 h. The membranes were then incubated overnight with anti-Ndufa5 (1:1,000; cat. no. 16640-1-AP; ProteinTech Group, Inc., Chicago, USA), anti-Ndufs6 (1:1,000; cat. no. 14417-1-AP; ProteinTech Group, Inc.), anti-ATP5A (1:1,000; cat. no. 14676-1-AP; ProteinTech

Table I. Body weights and liver weights of rats.

Parameter	Con (n=6)	HFD (n=10)
Initial body weight (g)	318.83 $\pm$ 19.31	321.30 $\pm$ 15.25
Final body weight (g)	516.50 $\pm$ 37.07	548.20 $\pm$ 22.23 <sup>a</sup>
Liver weight (g)	11.71 $\pm$ 1.17	16.56 $\pm$ 3.26 <sup>b</sup>
Liver weight/body weight (%)	2.26 $\pm$ 0.22	3.02 $\pm$ 0.57 <sup>b</sup>

Values are expressed as the mean  $\pm$  standard deviation. <sup>a</sup> $P < 0.05$  and <sup>b</sup> $P < 0.01$ , vs. Con group. Con, control; HFD, high fat and high cholesterol diet.

Table II. Serum biochemical parameters.

Parameter (mM)	Con (n=6)	HFD (n=10)
Glucose	10.92 $\pm$ 0.90	10.49 $\pm$ 2.10
TG	0.56 $\pm$ 0.13	0.64 $\pm$ 0.10
TC	1.66 $\pm$ 0.41	2.44 $\pm$ 0.48 <sup>a</sup>
LDL-C	1.07 $\pm$ 0.35	1.86 $\pm$ 0.43 <sup>a</sup>
HDL-C	0.34 $\pm$ 0.11	0.29 $\pm$ 0.13

Values are expressed as the mean  $\pm$  standard deviation. <sup>a</sup> $P < 0.01$ , vs. Con. TC, total cholesterol; TG, triglyceride; LDL-C, low-density lipoprotein; HDL-C, high-density lipoprotein; Con, control; HFD, high fat and high cholesterol diet.

Group, Inc.), anti-TFAM (1:1,000; cat. no. ab131607; Abcam) and CytB (1:1,000; cat. no. 55090-1-AP; ProteinTech Group, Inc.) at 4°C. The membranes were washed once with TBST buffer and incubated with horseradish peroxidase-conjugated anti-rabbit secondary antibodies (1:3,000; cat. no. A0208; Beyotime Institute of Biotechnology) at room temperature for 1 h. The intensity of the bands was detected using ECL Western Blotting Substrate (Thermo Fisher Scientific, Inc.).

**Statistical analysis.** All results are presented as the mean  $\pm$  standard deviation and data were analyzed using Student's t-test. Statistical analyses were performed with SPSS 20.0 (IMB SPSS, Armonk, NY, USA).  $P < 0.05$  was considered to indicate a statistically significant difference.

## Results

**Characterization of the NASH rat model.** The 16 weeks of HFD feeding successfully induced hepatic steatohepatitis. The body weights of the rats, compared with those in the control group, were significantly increased in the HFD group ( $P < 0.05$ ; Table I). Of note, HFD chow resulted in a marked increase in the liver weight and hepatic index (liver weight/body weight %). Higher levels ( $P < 0.01$ ) of serum TC and LDL-C were also found in the HFD-fed rats, compared with those in the controls, although no significant differences were found in the TG, HDL-C or glucose levels (Table II). Following 16 weeks of HFD feeding, the livers sections showed that there were abundant macrovesicular fat droplets




Figure 1. Hepatic pathology. Liver sections from the Con and HFD groups were stained with hematoxylin and eosin. Representative images from (A) Con and (B) HFD groups at x100 magnification. Representative images from (C) Con and (D) HFD groups at x400 magnification. Fat droplets, ballooned hepatocytes and inflammatory cells are present in the HFD group. HFD, high fat and high cholesterol diet; Con, control; HFD, high fat and high cholesterol diet.

in the hepatocytes and increased quantities of ballooned hepatocytes in the centrilobular parenchyma, leading to destruction of the normal structure of numerous hepatic lobules (Fig. 1). Furthermore, foci of necrosis and infiltration of inflammatory cells were identified in the centrilobular region. The liver tissues of the control group showed no histological abnormalities (Fig. 1).

**Effect of mtDNA copy number.** The present study also evaluated alterations of mitochondrial biogenesis in rats with HFD-induced NASH using information on mtDNA copy number. HFD feeding induced a significant decrease ( $P < 0.05$ ) in mtDNA copy number, which was reflected in the ratio of ND<sub>1</sub> DNA to actin DNA in the liver (Fig. 2).

**Evaluation of MRC and MMP.** As MRCs are pivotal in the generation of energy by oxidative phosphorylation, the present study measured whether the activity of the MRC was affected in the liver tissues of the HFD group. As shown in Fig. 3A, the activity of complex I was significantly reduced in the HFD group, compared with that in the control group (complex I/CS,  $1.93 \pm 0.56$  vs.  $2.72 \pm 0.67$ ;  $P < 0.05$ ). No difference was observed in complex II (Fig. 3B), however, the activity of complex III was also significantly lower in the HFD group, compared with that in the control group (complex III/CS,  $1.39 \pm 0.29$  vs.  $1.81 \pm 0.24$ ;  $P < 0.05$ ), as shown in Fig. 3C. No significant differences were observed in complex IV or ATP synthase (Fig. 3D and E). Citrate synthase is usually regarded as a quantitative marker enzyme for the content of intact mitochondria, and no significant change was detected between the HFD group and the control group (Fig. 3F). HFD chow also led to loss of MMP, which was associated with mitochondrial dysfunction (Fig. 4).




Figure 2. Evaluation of mtDNA copy numbers were evaluated in livers from rats in the Con and HFD groups via analysis of the ratio of ND<sub>1</sub> DNA to actin DNA. The ND<sub>1</sub> gene belongs to the mitochondrial genome, and actin gene belongs to the nuclear genome. Values are presented as the mean  $\pm$  standard deviation. \* $P < 0.05$ , vs. Con group. HFD, high fat and high cholesterol diet; Con, control; mtDNA, mitochondrial DNA.

**Mitochondrial proteomic profiling analysis.** In order to fully understand the pivotal role of mitochondria dysfunction in NASH, the present study measured the mitochondrial protein profiles of the liver from the HFD group model using iTRAQ labeling technology. A total of 61 significantly differentially expressed proteins were identified and were synchronous with the comparisons of liver mitochondrial samples isolated from the control and HFD groups. Compared with the control group, 30 upregulated proteins with a fold change  $> 1.0$  and 31 downregulated proteins




Figure 3. Analysis of mitochondrial respiratory chain enzymes in liver mitochondria isolated from control and HFD groups. Complexes (A) I, (B) II, (C) III, and (D) IV. Complex activities were normalized to CS. (E) ATP synthase activity (F) CS activity. The values are expressed as the mean  $\pm$  standard deviation. \* $P < 0.05$ , vs. Con group. HFD, high fat and high cholesterol diet; Con, control; CS, citrate synthase.




Figure 4. MMP was reflected by the ratio of red and green fluorescence. Liver mitochondria from the Con and HFD groups were isolated for MMP analysis. The values are presented as the mean  $\pm$  standard deviation. \*\* $P < 0.01$  vs. Con group. MMP, mitochondrial membrane potential; HFD, high fat and high cholesterol diet; Con, control.

with a fold change  $< 1.0$  were observed in the HFD group, subsequently, 18 upregulated (Table III) with a fold change  $> 1.2$  and 13 downregulated proteins (Table IV) with a fold change  $\leq 0.8$  were selected. The biological processes were found to be associated with dysregulated proteins using the GO database. Of note, the majority of these differentially expressed proteins were closely involved, including mitochondrial oxidative phosphorylation, lipid metabolic process, acyl-CoA metabolic process and fatty acid  $\beta$ -oxidation (Table V). In the HFD group, proteins involved in mitochondrial oxidative phosphorylation were almost unanimously downregulated, compared with the control group. Among the dysregulated proteins, seven decreased proteins, including Ndufc2, Ndufs6, Ndubf3, Ndufa2, Ndufa5, Ndubf5 and NADH-ubiquinone oxidoreductase chain 5 (ND<sub>5</sub>), were component parts of mitochondrial complex II and the decreased proteins, ubiquinol-cytochrome c reductase, complex III subunit X (UQCRI0) and cytochrome B (CytB) were the subunits of mitochondrial

Table III. Identification of 18 mitochondrial proteins upregulated in the high fat and high cholesterol diet group, compared with the control group, using isobaric tags for relative and absolute quantitation labeling technology.

Accession no.	Protein name	Gene name	Fold change
trlQ5U2U5IQ5U2U5_RAT	Perilipin 2	Plin2	3.61
splO70490IACSM2_RAT	Acyl-coenzyme A synthetase	ACSM2	2.02
splP61354IRL27_RAT	60S ribosomal protein L27	Rpl27	1.94
splQ5EB77IRAB18_RAT	Ras-related protein Rab-18	Rab18	1.90
trlD3ZSY4ID3ZSY4_RAT	Eosinophil peroxidase	Epx	1.68
trlF1LRE2IF1LRE2_RAT	Insulin-like growth factor-binding protein complex acid labile subunit	Igfals	1.68
splP55159IPON1_RAT	Serum paraoxonase/arylesterase 1	Pon1	1.64
splP11915INLTP_RAT	Non-specific lipid-transfer protein	Scp2	1.47
splP07687IHYEP_RAT	Epoxide hydrolase 1	Ephx1	1.45
splP07871ITHIKB_RAT	3-ketoacyl-CoA thiolase B	Acaa1b	1.44
trlG3V743IG3V743_RAT	Glucosidase 1	Mogs	1.35
splQ5BJY9IK1C18_RAT	Keratin, type I cytoskeletal 18	Krt18	1.32
trlD4ABM5ID4ABM5_RAT	Mitochondrial ribosomal protein S34	Mrps34	1.31
splQ4FZX5IMSRB2_RAT	Methionine-R-sulfoxide reductase B2	MsrB2	1.30
splP63095IGNAS2_RAT	Guanine nucleotide-binding protein G(s) subunit $\alpha$ isoforms	Gnas	1.27
splP41034ITTPA_RAT	$\alpha$ -tocopherol transfer protein	Ttpa	1.25
splQ5U3Z3IISOC2_RAT	Isochorismatase domain-containing protein 2	Isoc2	1.24
trlF6Q5K7IF6Q5K7_RAT	Mitochondrial ribosomal protein S18B	Mrps18b	1.22

Fold-changes of >1.2 and P<0.05 for all statistical data.

Table IV. Identification of 13 mitochondrial proteins downregulated in the high fat and high cholesterol diet group, compared with the control group, using isobaric tags for relative and absolute quantitation labeling technology.

Accession no.	Protein name	Gene name	Fold change
trlF1LMQ2IF1LMQ2_RAT	Farnesyl pyrophosphate synthase	FPPS	0.46
splO35760IID11_RAT	Isopentenyl-diphosphate $\delta$ -isomerase 1	Idi1	0.47
trlQ5PQZ9IQ5PQZ9_RAT	NADH dehydrogenase [ubiquinone] 1 subunit C2	Ndufc2	0.64
splP11951ICX6C2_RAT	Cytochrome <i>c</i> oxidase subunit 6C-2	Cox6c2	0.64
trlB2RYX1IB2RYX1_RAT	Cytochrome b-c1 complex subunit 9	Uqcrl0	0.65
trlD3ZCZ9ID3ZCZ9_RAT	NADH dehydrogenase [ubiquinone] iron-sulfur protein 6	Ndufs6	0.65
splQ63362INDUA5_RAT	NADH dehydrogenase [ubiquinone] 1 $\alpha$ subcomplex subunit 5	Ndufa5	0.66
trlD4A4P3ID4A4P3_RAT	NADH dehydrogenase [ubiquinone] 1 $\beta$ subcomplex subunit 3	Ndufb3	0.69
trlB0M1Q8IB0M1Q8_RAT	Cytochrome b	CytB	0.72
trlD3ZS58ID3ZS58_RAT	NADH dehydrogenase [ubiquinone] 1 $\alpha$ subcomplex subunit 2	Ndufa2	0.72
trlD4A565ID4A565_RAT	NADH dehydrogenase (ubiquinone) 1 $\beta$ subcomplex, 5	Ndufb5	0.72
trlQ06QA1IQ06QA1_RAT	NADH-ubiquinone oxidoreductase chain 5	ND <sub>5</sub>	0.76
splQ6PCT8IDHSD_RAT	Succinate dehydrogenase [ubiquinone] cytochrome b small subunit	Sdhb	0.80

Fold changes of  $\leq$ 0.8 and P<0.05 for all statistical data.

complex III. In the inner mitochondrial membrane, these proteins form the middle segment of the respiratory chain. The decrease in these proteins coincided with the significant decline in the activities of complexes I and III (Fig. 3A and B). These proteomics may provide novel insights into pathogenesis of NASH, although further functional investigations are required to specify proteins.

**Western blot analysis.** The western blot analysis confirmed the differentially expressed proteins identified using iTRAQ technology. For the analysis, four proteins of interest were selected (Ndufa5, CytB, ATP5A and TFAM). Voltage-dependent anion-selective channel 1 (VDAC<sub>1</sub>) was used as the loading control. The expression levels of Ndufa5 and CytB were significantly decreased in the HFD group,

Table V. Dysregulated proteins involved in biological processes, according to the Gene Ontology database.

Biological process	Change in expression
Mitochondrial oxidative phosphorylation	
NADH dehydrogenase [ubiquinone] 1 subunit C2	Downregulated
NADH dehydrogenase [ubiquinone] iron-sulfur protein 6	Downregulated
NADH dehydrogenase [ubiquinone] 1 $\beta$ subcomplex subunit 3	Downregulated
NADH dehydrogenase [ubiquinone] 1 $\alpha$ subcomplex subunit 2	Downregulated
NADH-ubiquinone oxidoreductase chain 5	Downregulated
NADH dehydrogenase [ubiquinone] 1 $\alpha$ subcomplex subunit 5	Downregulated
Succinate dehydrogenase [ubiquinone] cytochrome b small subunit	Downregulated
Cytochrome b	Downregulated
Cytochrome b-c1 complex subunit 9	Downregulated
Lipid metabolic process	
Perilipin2	Upregulated
Acyl-coenzyme A synthetase	Upregulated
Arylsulfatase B	Upregulated
Estradiol 17- $\beta$ -dehydrogenase 11	Upregulated
Non-specific lipid-transfer protein	Upregulated
3-ketoacyl-CoA thiolase B	Upregulated
Farnesyl pyrophosphate synthase	Downregulated
Isopentenyl-diphosphate $\delta$ -isomerase 1	Downregulated
Cytochrome P450 2D18	Downregulated
Acyl-CoA-binding protein	Downregulated
Acyl-CoA metabolic process	
Acyl-coenzyme A synthetase	Upregulated
Non-specific lipid-transfer protein	Upregulated
Acyl-CoA-binding protein	Downregulated
$\alpha$ -aminoadipic semialdehyde synthase	Downregulated
Fatty acid $\beta$ -oxidation	
Non-specific lipid-transfer protein	Upregulated
3-ketoacyl-CoA thiolase B	Upregulated

compared with the control group, whereas no significant differences were observed in the levels of TFAM and ATP5A between the HFD group and control group. These findings were in accordance with the results obtained using iTRAQ technology (Fig. 5).

## Discussion

NASH is considered to be important in the progression of NAFLD, which can progress into cirrhosis and subacute liver failure (1). However, the primary underlying mechanism contributing to the pathogenesis of NASH remains to be fully elucidated. The principal function of the mitochondria is to provide energy to maintain several cell functions. Previous studies have linked mitochondrial dysfunction and oxidative stress to the pathogenesis of NASH (7). Furthermore, mitochondrial structural abnormalities and decreased activity of MRCs have been reported in the livers of patients with NASH (13). In the present study, comprehensive analysis of liver mitochondrial proteomics was performed to provide a novel perspective for the pathophysiology of the condition.

In the proteomic analysis, a number of proteins involved in mitochondrial oxidative phosphorylation and the metabolism of lipids were significantly dysregulated, which may have contributed to the progression of NASH. For example, proteins in MRC complexes decreased significantly, including Ndufc2, Ndufs6, Ndufb3, Ndufa2, Ndufa5, Ndufb5, ND<sub>5</sub> (complex I), Sdh (complex II), Cox6c2, Uqcr10 and CytB (complex III). Ndufc2 is one of the accessory subunits of complex I. The downregulation of Ndufc2 can decrease MMP and interfere with complex I integrity (13). The expression of Ndufb3 and Ndufb5, which are members of mitochondrial complex I, can be decreased by HFD, resulting in the dysfunction of mitochondrial oxidative phosphorylation in skeletal muscle (14). Ndufa5 localizes to the inner mitochondrial membrane, and its expression is reduced in the brains of patients with autism and in ischemic heart failure (15,16), involving organs with high energy demand. The expression levels of ND<sub>5</sub>- and cytochrome b-encoded mtDNA were decreased, which can be correlated with mtDNA depletion. The changes of 10 proteins in the mitochondrial complex was consistent with decreased activities of complex II and III. However, the downregulation of






Figure 5. Western blot analysis validation of mitochondrial proteins. Liver mitochondrial expression levels of ATP5A, CytB, TFAM and Ndufa5 between the Con and HFD groups. VDAC<sub>1</sub> was used as a loading control. (A) Images of the western blots from four biological replicates. (B) Bar graphs of the results of the western blot analysis. The values are presented as the mean  $\pm$  standard deviation. \* $P < 0.05$  and \*\* $P < 0.01$ , vs. Con group. HFD, high fat and high cholesterol diet; Con, control; ATP5A, ATP synthase  $\alpha$  subunit; CYTB, cytochrome b; TFAM, transcription factor A, mitochondrial; Ndufa5, NADH dehydrogenase [ubiquinone] 1 $\alpha$  subcomplex subunit 5; VDAC<sub>1</sub>, voltage-dependent anion-selective channel 1.

Sdh did not decrease the activity of complex II. Mitochondria complex I is critical in transferring electrons to ubiquinone. Complex I deficiency has been reported in several diseases, including heart failure, myopathies, encephalomyopathies and neurodegenerative disorders (17,18). Furthermore, complex I and III are two sites of ROS generation in cells (19). It is well established that the administration of a HFD in rats leads to the profound modification of mitochondrial lipid composition, causes the inhibition of fatty acid oxidation and the generation of mitochondrial ROS (20). In terms of MRC activity, ROS are overproduced following any significant reduction, which triggers oxidative stress (7). ROS has been implicated in the hepatic tissue injury associated with NASH (5). The depletion of mtDNA in the HFD group may be associated with ROS, which leads to the degradation of mtDNA nucleases. Complex I abnormality may result in increasing ROS production, and ROS conversely affects the activity of mitochondrial complex I through the oxidative damage of cardiolipin (21), which can exacerbate oxidative stress and potentially contribute to the pathogenesis of NASH. In the present study, the decrease in components of complex I and III were expected to decrease complex activity with increasing ROS, which may be relevant to the decrease of MMP and be involved in the progression of NASH.

The present study also found several dysregulated proteins associated with preventing the progression of NASH. Non-specific lipid transfer protein (Scp2) is located in the cytoplasm and mitochondria (22). It has high affinity to several lipid species, including fatty acid, fatty acyl CoAs, lysophosphatidic acid, and phosphatidylinositol, and is also involved in the mitochondrial oxidation of cholesterol in cells (23).

Tumor necrosis factor and Fas, released by mitochondrial-free cholesterol, also induces NASH (24). Therefore, the upregulation of Scp2 may be a protective response to excess lipids in NASH. Medium-chain length fatty acids and xenobiotic carboxylic acids were catalyzed by the upregulation of acyl CoA synthetase (ACSM2) in the HFD group. In the liver, the decreased expression of ACSM2 can lead to an increase of free medium-chain fatty acids. Following treatment with medium-chain fatty acids, the protein level of the transcription factor, SREBP-1, is reduced and has a contrasting reaction to that of insulin in primary chicken hepatocytes (25). NASH is associated with insulin resistance, including lipolysis increase, free fatty acid delivery and hepatic fatty acid  $\beta$  oxidation, which lead to an increase in oxidative stress (6). Therefore, ACSM2 may indirectly enhance insulin function in hepatocytes, which may be a protective response to insulin resistance in the liver. However, the specific generating process requires further investigation.

Among the downregulated proteins, farnesyl pyrophosphate synthase and Isopentenyl-diphosphate  $\delta$ -isomerase 1 are two enzymes of the mevalonate pathway, which catalyzes the synthesis of farnesyl pyrophosphate (FPP) in mitochondria (26). As with ubiquinones in the electron transport chain, mitochondrial isoprenoids are synthesized by FPP. However, the detailed association between FPP and the development of NASH remains to be fully elucidated.

In conclusion, the present study reports the protein profiling in NASH liver mitochondria using iTRAQ technology to perform detailed analysis of the pathogenesis of NASH for the first time. The results revealed 31 differentially expressed proteins in the NASH rat model, compared with the control rats. The dysregulation of proteins in NASH were predominantly associated with the MRC and lipid metabolic process. However, these proteins require further investigation for elucidating the molecular mechanism underlying the pathogenesis of NASH.

#### Acknowledgements

The present study was supported by a grant from the National Basic Research Program of China (grant no. 2013CB531702).

#### References

- Patrick Melin AJ, Kalinski MI, Kelly KR, Haus JM, Solomon TP and Kirwan JP: Nonalcoholic fatty liver disease: Biochemical and therapeutic considerations. *Ukr Biokhim Zh* (1999) 81: 16-25, 2009.
- Masuoka HC and Chalasani N: Nonalcoholic fatty liver disease: An emerging threat to obese and diabetic individuals. *Ann N Y Acad Sci* 1281: 106-122, 2013.
- Day CP and James OF: Steatohepatitis: A tale of two 'hits'? *Gastroenterology* 114: 842-845, 1998.
- Day CP: From fat to inflammation. *Gastroenterology* 130: 207-210, 2006.
- Pessayre D and Fromenty B: NASH: A mitochondrial disease. *J Hepatol* 42: 928-940, 2005.
- Sanyal AJ, Campbell Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, Luketic VA, Shiffman ML and Clore JN: Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities. *Gastroenterology* 120: 1183-1192, 2001.
- Begriche K, Igoudjil A, Pessayre D and Fromenty B: Mitochondrial dysfunction in NASH: Causes, consequences and possible means to prevent it. *Mitochondrion* 6: 1-28, 2006.

8. Anstee QM and Goldin RD: Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. *Int J Exp Pathol* 87: 1-16, 2006.
9. Ye H, Sun L, Huang X, Zhang P and Zhao X: A proteomic approach for plasma biomarker discovery with 8-plex iTRAQ labeling and SCX-LC-MS/MS. *Mol Cell Biochem* 343: 91-99, 2010.
10. Pallotti F and Lenaz G: Isolation and subfractionation of mitochondria from animal cells and tissue culture lines. *Methods Cell Biol* 80: 3-44, 2007.
11. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the  $2^{-\Delta\Delta C(T)}$  method. *Methods* 25: 402-408, 2001.
12. Wieckowski MR, Giorgi C, Lebiecinska M, Duszynski J and Pinton P: Isolation of mitochondria-associated membranes and mitochondria from animal tissues and cells. *Nat Protoc* 4: 1582-1590, 2009.
13. Pérez Carreras M, Del Hoyo P, Martín MA, Rubio JC, Martín A, Castellano G, Colina F, Arenas J and Solís Herruzo JA: Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. *Hepatology* 38: 999-1007, 2003.
14. Sparks LM, Xie H, Koza RA, Mynatt R, Hulver MW, Bray GA and Smith SR: A high-fat diet coordinately downregulates genes required for mitochondrial oxidative phosphorylation in skeletal muscle. *Diabetes* 54: 1926-1933, 2005.
15. Anitha A, Nakamura K, Thanseem I, Matsuzaki H, Miyachi T, Tsujii M, Iwata Y, Suzuki K, Sugiyama T and Mori N: Downregulation of the expression of mitochondrial electron transport complex genes in autism brains. *Brain Pathol* 23: 294-302, 2013.
16. Liu T, Chen L, Kim E, Tran D, Phinney BS and Knowlton AA: Mitochondrial proteome remodeling in ischemic heart failure. *Life Sci* 101: 27-36, 2014.
17. Kang PT, Chen CL, Ren P, Guarini G and Chen YR: BCNU-induced gR2 defect mediates S-glutathionylation of Complex I and respiratory uncoupling in myocardium. *Biochem Pharmacol* 89: 490-502, 2014.
18. Finsterer J, Rauschka H, Segal L, Kovacs GG and Rolinski B: Affection of the respiratory muscles in combined complex I and IV deficiency. *Open Neurol J* 11: 1-6, 2017.
19. Murphy MP: How mitochondria produce reactive oxygen species. *Biochem J* 417: 1-13, 2009.
20. Vial G, Dubouchaud H, Couturier K, Cottet Rousselle C, Taleux N, Athias A, Galinier A, Casteilla L and Leverve XM: Effects of a high-fat diet on energy metabolism and ROS production in rat liver. *J Hepatol* 54: 348-356, 2011.
21. Paradies G, Petrosillo G, Pistolesi M and Ruggiero FM: Reactive oxygen species affect mitochondrial electron transport complex I activity through oxidative cardiolipin damage. *Gene* 286: 135-141, 2002.
22. Gallegos AM, Atshaves BP, Storey SM, Starodub O, Petrescu AD, Huang H, McIntosh AL, Martin GG, Chao H, Kier AB and Schroeder F: Gene structure, intracellular localization, and functional roles of sterol carrier protein-2. *Prog Lipid Res* 40: 498-563, 2001.
23. Schroeder F, Atshaves BP, McIntosh AL, Gallegos AM, Storey SM, Parr RD, Jefferson JR, Ball JM and Kier AB: Sterol carrier protein-2: New roles in regulating lipid rafts and signaling. *Biochim Biophys Acta* 1771: 700-718, 2007.
24. Mari M, Caballero F, Colell A, Morales A, Caballeria J, Fernandez A, Enrich C, Fernandez Checa JC and Garcia Ruiz C: Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis. *Cell Metab* 4: 185-198, 2006.
25. Zhang Y, Yin L and Hillgartner FB: SREBP-1 integrates the actions of thyroid hormone, insulin, cAMP, and medium-chain fatty acids on ACC $\alpha$  transcription in hepatocytes. *J Lipid Res* 44: 356-368, 2003.
26. Martín D, Piulachs MD, Cunillera N, Ferrer A and Bellés X: Mitochondrial targeting of farnesyl diphosphate synthase is a widespread phenomenon in eukaryotes. *Biochim Biophys Acta* 1773: 419-426, 2007.